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Abstract: In this report, we used hydrogen exchange-mass spectrometry (HX-MS) to identify
the epitopes recognized by 21 single-domain camelid antibodies (VHHs) directed against the
ribosome-inactivating subunit (RTA) of ricin toxin, a biothreat agent of concern to military and public
health authorities. The VHHs, which derive from 11 different B-cell lineages, were binned together
based on competition ELISAs with IB2, a monoclonal antibody that defines a toxin-neutralizing
hotspot (“cluster 3”) located in close proximity to RTA’s active site. HX-MS analysis revealed that
the 21 VHHs recognized four distinct epitope subclusters (3.1–3.4). Sixteen of the 21 VHHs grouped
within subcluster 3.1 and engage RTA α-helices C and G. Three VHHs grouped within subcluster
3.2, encompassing α-helices C and G, plus α-helix B. The single VHH in subcluster 3.3 engaged RTA
α-helices B and G, while the epitope of the sole VHH defining subcluster 3.4 encompassed α-helices
C and E, and β-strand h. Modeling these epitopes on the surface of RTA predicts that the 20 VHHs
within subclusters 3.1–3.3 physically occlude RTA’s active site cleft, while the single antibody in
subcluster 3.4 associates on the active site’s upper rim.
Keywords: toxin; antibody; camelid; vaccine; biodefense; hydrogen exchange-mass spectrometry
1. Introduction
Ricin is a member of the ribosome-inactivating protein (RIP) family of toxins and classified as
a biothreat agent due to its high potential to induce morbidity and mortality after inhalation [1–3].
The toxin is a ~65 kDa heterodimeric glycoprotein from the castor bean plant (Ricinus communis)
consisting of a binding subunit (RTB) and an enzymatic subunit (RTA). RTB is a galactose/N-acetyl
galactosamine (Gal/GalNAc)-specific lectin that promotes toxin attachment and entry into mammalian
cells [4]. RTA is an RNA N-glycosidase (EC 3.2.2.22) that depurinates a conserved adenosine within
the sarcin-ricin loop (SRL) of 28S rRNA, thereby stalling ribosome translocation [5,6]. At the structural
level, RTA is a globular protein with a total of 10 β-strands (A–J) and seven α-helices (A–G). RTA folds
into three distinct domains: domain 1 (residues 1–117) is dominated by a six-stranded β-sheet, domain
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2 (residues 118–210), by five α-helices, and domain 3 (residues 211–267), which interfaces with RTB
through hydrophobic interactions and a single disulfide bond [7,8]. RTA’s active site constitutes
a shallow pocket formed at the interface of the three domains [8,9]. Active site residues include Tyr80,
Tyr123, Glu177, Arg180, and Trp211 (Figure 1A) [10].
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ricin exposure is strictly supportive [15]. However, vaccination strategies have shown great promise 
in affording complete or near complete protection against ricin intoxicosis in mice and NHPs [16]. 
For example, intramuscular administration of RiVax, a non-toxic thermostabilized recombinant RTA-
based subunit vaccine adjuvanted with aluminum salts, to Rhesus macaques was sufficient to confer 
immunity to a lethal dose (LD) ricin challenge delivered by aerosol [14]. In vivo neutralization of ricin 
toxin following vaccination is associated with onset of anti-RTA IgG antibodies in serum and 
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confer immunity to a lethal dose (LD) ricin challenge delivered by aerosol [14]. In vivo neutralization
of ricin toxin following vaccination is associated with onset of anti-RTA IgG antibodies in serum and
bronchoalveolar lavage (BAL) fluid [13,14,17].
Monoclonal (mAb) and polyclonal (pAb) antibody responses in mice, rabbits, and NHPs elicited
by RiVax vaccination are directed against four spatially distinct immunodominant regions on RTA,
which we refer to as epitope clusters 1–4 [11,18–23]. A combination of competition ELISAs, X-ray
crystallography, and hydrogen exchange-mass spectrometry (HX-MS) has revealed key secondary
elements associated with each cluster. Cluster 1 encompasses RTA’s β-strand h (residues 113–117) and
α-helix B (94–107), a protruding immunodominant secondary structure element previously known
to be a target of potent toxin-neutralizing antibodies [24]. Cluster 2 consists of two subclusters: one
involving α-helix A (14–24) and α-helices F–G (184–207) and the other encompassing β-strands d-e
(62–69) and parts of α-helices D–E (154–164). Cluster 3 involves α-helices C (121–135) and G (207–217)
near RTA’s active site, while Cluster 4 is proposed to form a diagonal sash from the front to back
of RTA spanning β-strands b, c, and d (35–59). Our long-term goal is to generate a comprehensive
molecular B-cell epitope map of each of these clusters and define the specific antibody-contact points
on RTA that render the toxin inactive. Such information will be invaluable in efforts to deconvolute
the complex human antibody response profile to ricin toxin and RiVax [25].
While much has been learned about clusters 1 and 2 over recent years, comparatively little is
known about cluster 3, as it is defined by only a single mAb called IB2 [11]. IB2 was first identified
as a toxin-neutralizing mouse mAb that, in competition ELISAs, proved to be distinct from other
mAbs in our collection at the time [18,26]. IB2 can passively protect mice against a 5 × LD50 ricin
challenge by injection, indicating it has neutralizing activity in vivo, and must, by definition, interact
with an important element on ricin toxin. As noted above, we recently demonstrated by HX-MS
analysis that IB2 recognizes an epitope involving RTA’s α-helix C (residues 121–135) and α-helix G
(residues 207–217), which is not only in close proximity to RTA’s active site but includes two active
site residues, Tyr123 and Trp211 (Figure 1B). However, efforts to interrogate cluster 3 in more detail
have been hindered by the absence other cluster 3-specific mAbs. Indeed, recent screens of B-cell
hybridomas derived from RiVax and ricin toxoid immunized mice failed to identify additional cluster
3 antibodies [27].
Whereas isolation of additional IB2-like mouse mAbs has not been fruitful, we did recently
identify 21 unique heavy chain-only single-domain camelid antibodies (VHHs) that are competed by
IB2 for binding to ricin toxin (D. Vance, C. Shoemaker, N. Mantis, manuscript in preparation) [23].
We wished to characterize these VHHs in detail with respect to their binding affinities, epitopes,
and capacities to neutralize ricin. In this report, we localized by HX-MS the epitopes of all 21 of
these VHHs. We found that the 21 VHHs fall within one of four distinct but overlapping subclusters
(3.1–3.4) that share at least one secondary element contacted by IB2. Only two of the 21 VHHs, V6D4
and V1D3, have appreciable toxin-neutralizing activity (TNA), which we speculate is due to their
epitope specificity along with strong binding affinity to toxin. This work furthers our overall goal of
constructing a complete B-cell epitope map of ricin toxin.
2. Materials and Methods
2.1. RiVax and VHH Production
RiVax was expressed and purified from E. coli, as described [28]. Please note that RiVax differs
from native RTA at two positions, which render the enzyme inactive: there is an Ala at position
80 substituted for Tyr, and a Met at position 76 in place of Val [29]. RiVax also lacks high mannose
residues normally found on RTA, due to the fact that RiVax is expressed in E. coli. In addition, the RiVax
used here has the addition of an Ala at the N-terminus, which we denoted as residue 0 for simplicity.
VHHs were expressed in E. coli as either thioredoxin- and E-tagged constructs or tag-free variants [22].
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2.2. Competition ELISA
NUNC microtiter plates (Fisher Scientific, Hampton, NH) were coated with competitor mAbs
(1 µg/mL in Phosphate Buffered Saline (PBS)) overnight at 4 ◦C and then blocked for 2 h with 2%
goat serum (Gibco, Gaithersburg, MD, USA) in 0.1% PBST. Ricin (1 µg/mL) (Vector Labs, Burlingame,
CA, USA) was then captured by the mAbs and probed with VHH analytes at 330 nM. Bound VHHs
were detected with an anti-E-tag-HRP secondary antibody (Bethyl Labs, Montgomery, TX, USA) and
developed with SureBlue 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (SeraCare, Milford, MA, USA).
After quenching with 1 M phosphoric acid (Sigma Aldrich, Carlsbad, CA, USA), absorbance was read
at 450 nm on a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA, USA). % inhibition
was calculated by comparing absorbance of captured VHHs on each mAb-ricin complex with that of
the absorbance of each VHH captured onto SylH3-ricin, where SylH3 is an anti-RTB mAb that does not
interfere with the binding of any VHHs to RTA’s cluster 3.
2.3. Vero Cell Cytotoxicity Assay
Vero cells were detached from culture dishes with trypsin (Gibco), seeded into white 96-well cell
culture treated plates (Fisher Scientific) (100 uL per well, 5 × 104 cells/mL) and allowed to adhere
overnight. The cells were then treated with Dulbecco’s Modified Eagle Medium (DMEM) alone, ricin
alone (10 ng/mL), or a mixture of ricin with VHHs at five-fold dilutions. After 2 h at 37 ◦C, the culture
medium was changed, and the cells were incubated at 37 ◦C for ~48 h. Viability was assessed using
CellTiter-GLO (Promega, Madison, WI, USA). All treatments were performed in triplicate and repeated
at least three times.
2.4. Affinity Determinations
VHH association and dissociation rates were determined by SPR using a ProteOn XPR36 system
(Bio-Rad Inc., Hercules, CA, USA). Ricin was immobilized on a general layer compact (GLC) chip
(Bio-Rad Inc.) equilibrated in PBS-0.005% Tween running buffer at a flow rate of 30 µL/min. Following
EDAC [N-ethyl-N=-(3-dimethylaminopropyl) carbodiimide hydrochloride] (200 mM)–sulfo-NHS
(N-hydroxysulfosuccinimide) (50 mM) activation (3 min), ricin was diluted in 10 mM sodium acetate
(pH 5.0) at either 4 µg/mL or 2 µg/mL and coupled for 2 min. A third vertical channel received
only acetate buffer and served as a reference channel. The surfaces were deactivated using 1 M
ethanolamine for 5 min. A ProteOn array system multichannel module (MCM) was rotated to the
horizontal orientation for affinity determination experiments. Each VHH was serially diluted in
running buffer and then injected at 50 µL/min for 180 s, followed by 1 to 3 h of dissociation. After each
experiment, the chip was regenerated with 10 mM glycine (pH 1.5) at 100 µL/min for 18 s, until the
response unit (RU) values had returned to baseline. All kinetic experiments were performed at 25 ◦C.
Kinetic constants for the antibody/ricin interactions were obtained with ProteOn Manager software
3.1.0 (Bio-Rad Inc.) using the Langmuir fit model.
2.5. HX-MS
HX-MS experiments for epitope mapping were conducted essentially as described previously [11].
Briefly, a H/DX PAL™ robotic system (LEAP Technologies, Morrisville, NC, USA) was used for sample
preparation, mixing and injection. For the free RiVax, 4 µL of 20 µM RiVax stock solution was incubated
with 36 µL of deuterated buffer (10 mM sodium phosphate, 150 mM sodium chloride, pD 7.4). For the
bound states, the stock solution had a final concentration of 20 µM RiVax and 40 µM VHH resulting
in 1:2 molar ratio of RiVax:VHH. Four µL of the stock was incubated with 36 µL of deuterated buffer.
Samples were incubated at 25 ◦C for five HX times between 13 s and 24 h and subsequently quenched
using 200 mM phosphate-4 M guanidine hydrochloride solution (pH 2.5) held at 0 ◦C. The quenched
samples were then injected onto an immobilized pepsin column where proteolysis occurs overlapping
peptides from RiVax. The peptides were desalted using a C18 trap and separated using a segmented
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gradient with water/acetonitrile/0.1% formic acid on a C18 column (Zorbax 300SB-C18 2.1 × 50 mm,
1.8 µm particle diameter, Agilent, Santa Clara, CA, USA). The entire liquid chromatography system
(immobilized pepsin column, C18 trap and a C18 RP-UHPLC column) was kept in a refrigerated
cabinet that is maintained at 0 ◦C to minimize back exchange. Nevertheless, the first two residues in
a peptide generally undergo rapid back exchange [30]. RiVax peptides were analyzed by an QTOF
mass analyzer (model 6530, Agilent Technologies, Santa Clara, CA, USA) for their increase in mass i.e.,
for deuterium uptake. All HX-MS measurements were based on triplicate independent HX reactions
of each labeling time.
2.6. Data Analysis
The HX-MS data processing was carried out using HDExaminer (version 2.3, Sierra Analytics,
Modesto, CA, USA). A total of 138 peptides (Table S1) that cover the entire sequence of RiVax were
analyzed. For each peptide, the magnitude of protection from each HX time was averaged and
normalized to its peptide length to obtain a ∆HX value, ∆HX = HXbound − HXbound, as described
previously [11]. The propagated standard error in delta HX was estimated as described in [31].
The magnitudes of delta HX values of overlapping peptides that span the entire RiVax are then
classified using K-means clustering into three categories and were colored as follows: strong protection,
intermediate protection, no significant protection. For visualization, the HX-MS results were mapped
onto the crystal structure of RiVax (PDB: 3SRP) [32] using PyMoL (The PyMOL Molecular Graphics
System; Schrodinger LLC, San Diego, CA, USA). For better visualization purpose, only overlapping
peptides that fall in strong and intermediate protection category are colored.
3. Results
3.1. Identification and Characterization of Cluster 3 VHHs
Using a variety of screening strategies that are described in detail in separate manuscripts (D.
Vance, J. Tremblay, C. Shoemaker, N. Mantis, manuscript in preparation) [23], we identified from
different phage-displayed alpaca single chain libraries a total of 21 VHHs whose binding to ricin
toxin was partially or completely inhibited by IB2 in a capture ELISA (Figure 2). The competitive
ELISA was designed such that IB2 was immobilized on microtiter plates and then allowed to capture
ricin in solution. The plates were washed to remove unbound ricin and then probed with query
VHHs, as described in the figure legend and Materials and Methods. The DNA sequences and mAb
competition profiles of ten of the VHHs were reported in a recent study, although only two (JNM-D1
and V1B11) HX-MS epitopes were described [23].
To further differentiate among the 21 VHHs, they were subjected to a more comprehensive
competition array using a panel of nine additional RTA-specific mAbs representing cluster 1 (PB10,
WECB2), cluster 1–2 (SWB1), cluster 2 (PH12, TB12, PA1, SyH7), and cluster IV (JD4, GD12) [11].
The competition ELISA revealed a wide range of profiles (Figure 2), indicating the 21 VHHs, as a whole,
represent a diversity of epitopes on RTA. Indeed, the predicted CDR3 amino acid sequences of the
21 VHHs suggest they represent at least 11 different B-cell lineages: five unique VHHs and 16 others
that fell into one of six sequence families (Table 1; Figure S1).






Figure 2. VHH binning by competition ELISA. (A) Ricin was captured on microtiter plates by anti-RTA mAbs (indicated along the top panel) or an anti-RTB mAb 
(SylH3) as a control. The plates were then probed with individual VHHs as indicated on the left most column and detected with a secondary E-tag antibody. Binding 
inhibition was calculated as 100 − (100 × (AmAb-Ricin/ASylH3-Ricin)) where interference by SylH3 was assumed to be negligible. The colored scale bar on far right indicates 
% inhibition. VHHs JIV-F5 and JIY-E1 were used as controls, since they are known to bind epitopes on RTA outside of IB2’s footprint. (B) The IB2 values from panel 
A are re-plotted for clarity to compare relative IB2 inhibition values and color coded based on subcluster designations described later in the manuscript. The two 
VHHs with toxin-neutralizing activity are denoted with an *. 
Figure 2. VHH binning by competition ELISA. (A) Ricin was captured on microtiter plates by anti-RTA mAbs (indicated along the top panel) or an anti-RTB mAb
(SylH3) as a control. The plates were then probed with individual VHHs as indicated on the left most column and detected with a secondary E-tag antibody. Binding
inhibition was calculated as 100 − (100 × ( mAb-Ricin/ASylH3-Ricin)) where interference by SylH3 was assumed to be negligible. The colored scale bar on far right
indicates % inhibition. VHHs JIV-F5 and JIY-E1 were used as controls, since they are known to bind epitopes on RTA outside of IB2’s footprint. (B) The IB2 values from
panel A are re-plotted for clarity to compare relative IB2 inhibition values and color co e base on subcluster designations described later in the manuscript. The two
VHHs with toxin- eutralizing activity are denoted with an *.
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Table 1. VHH Families based on CDR3 similarity.
Family Members




V6A6 V6A7, V6G10, V8C7, V8E6
V6D4 * V6B4
*, indicates VHHs with toxin-neutralizing activity; The following VHHs were not assigned to a family: JNM-A11,
JNM-D1, V1B11, V5A2, V7H7.
The binding kinetics of each VHH for ricin holotoxin was determined by surface plasmon
resonance (SPR). Twelve of the 21 VHHs had dissociation constants (Kd) of greater than 1 nM, while
the remaining nine had dissociation constants ranging from 0.2–1 nM (Table 2; Figure S2). The VHHs
were also tested for ricin TNA in a Vero cell assay. Only two VHHs, V6D4 (IC50, 200 nM) and V1D3
(IC50, 80 nM), had demonstrable TNA (Figure S3). Neutralizing activity was not solely a function
of binding affinity, as several VHHs with KDs comparable to V6D4 and V1D3 lacked detectable
neutralizing activity. For that reason, we sought to localize the epitopes on RTA recognized by each
of the 21 VHHs with the expectation that such information would offer insight into the basis of
toxin-neutralizing activity.
Table 2. Cluster 3 VHH TNA and Binding Affinities.
VHH Subcluster IC50 (nM) KD a (nM) kon b koff c
V1D3 3.1 80 0.460 3.15 × 105 1.45 × 10−4
V8C7 - 0.597 1.58 × 105 9.40 × 10−5
V6B4 - 0.652 1.70 × 105 1.11 × 10−4
V8E6 - 0.830 1.26 × 105 1.04 × 10−4
V1B10 - 0.917 8.29 × 104 7.60 × 10−5
V6A6 - 0.996 5.06 × 105 5.04 × 10−4
V6H8 - 1.150 6.63 × 104 7.66 × 10−5
V2G10 - 1.160 8.48 × 104 9.84 × 10−5
JNM-D1 - 1.190 1.80 × 105 2.15 × 10−4
V6G10 - 1.270 1.77 × 105 2.24 × 10−4
V5A2 - 1.460 2.15 × 105 3.14 × 10−4
V6A7 - 1.760 7.70 × 104 1.36 × 10−4
V2A11 - 1.820 2.97 × 104 5.41 × 10−5
JIV-F6 - 1.860 1.94 × 105 3.61 × 10−4
V1G6 - 5.340 3.05 × 104 1.63 × 10−4
V1B11 - 8.840 2.76 × 104 2.44 × 10−4
V7H7 3.2 - 0.507 1.65 × 105 8.36 × 10−5
V6D8 - 1.130 2.14 × 105 2.41 × 10−4
V6F12 - 1.210 1.80 × 105 2.17 × 10−4
V6D4 3.3 200 0.222 1.44 × 105 3.21 × 10−5
JNM-A11 3.4 - 0.212 4.20 × 105 8.91 × 10−5
a, determined by SPR with Langmuir fit model; b, 1/Ms; c, 1/s.
3.2. VHH Epitope Mapping by HX-MS
We have previously used HX-MS to localize more than two dozen VHH and mAb epitopes on RTA
or on RiVax, an attenuated recombinant RTA subunit vaccine antigen with point mutations at positions
V76 and Y80 [11,23,27,31,33]. We used RiVax in place of RTA because it is non-toxic to humans and
therefore poses no hazard to research staff. RiVax also assumes a tertiary structure essentially identical
to RTA [32]. Therefore, HX-MS was performed with RiVax in the presence of two-fold molar excess
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of each of the cluster 3 VHHs at five exchange times between 13 s and 24 h. Epitope assignment
was based on reduced (slower) HX exchange for peptides in the presence of a VHH, as compared
to RiVax alone. For example, in the presence of V6B4, the HX rate in the peptide corresponding
to RiVax residues 57–60 was unaltered, whereas there was much slower exchange observed for the
peptide corresponding to residues 206–218 (Figure 3). While reduced hydrogen exchange is generally
attributed to direct antibody-protein interaction, we cannot necessarily exclude possible allosteric
effects that may occur upon antibody engagement, especially when reduced exchange is observed at a
distance not consistent with being part of a core epitope [11].
Figure 3. Hydrogen exchange (HX) kinetics of two representative RiVax peptides in presence of V6B4.
Hydrogen deuterium exchange kinetics of two representative RiVax peptides in presence of V6B4.
(A) Peptide 14 (56–59), where the HX rate was not affected by association with V6B4. (B) Peptide 94
(205–217) where the rate of HX was substantially slowed by V6B4. Significance limit for HX differences
was defined as described in the Experimental section.
3.3. Identification of Epitope Subclusters
The results of epitope mapping studies revealed that the Cluster 3 VHHs grouped within four
subclusters, referred to as 3.1–3.4 (Table 3; Table S2;). Subcluster 3.1 involves contact with RiVax
α-helices C and G, a profile very similar to mAb IB2. Subcluster 3.2 encompasses α-helices B, C and G,
while subcluster 3.3 covers α-helices B and G, but not α-helix C. Finally, subcluster 3.4 encompasses
α-helices C and E, but not G. Each of these subclusters is now described in more detail.
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Table 3. Localization of epitopes on RiVax recognized by representative Cluster 3 VHHs.
Strong and Intermediate Protected Elements in RiVax a
VHH Subcluster Peptides Residues Structure(s)
V6B4 3.1 48–51 119–133 α-helix C
91–102 205–217 α-helix G
132–134 249–255 C-terminus
V1D3 * 54,55 127–135 α-helix C
91 205–210 α-helix G
112–116 226–243 β-strands i, j
132–134 249–255 C-terminus
V6D8 3.2 35–39 92–107 α-helix B
49–54 123–135 α-helix C
102 211–217 α-helix G
129–134 247–255 C-terminus
V6F12 35–40 92–107 α-helix B
47,49 118–126 α-helix C
94,97,100,102–103 205–217 α-helix G
132–134 249–255 C-terminus
V7H7 35–39 92–107 α-helix B
49 123–126 α-helix C
94–95,97–98,100,102 205–217 α-helix G
129–131 249–255 C-terminus
V6D4 * 3.3 35–37,39 92–107 α-helix B
102 211–217 α-helix G
132–134 249–255 C-terminus
JNM-A11 3.4 45,46 108–122 β-strand h
49–51 124–133 α-helix C
70,71 162–168 α-helix E
a, Peptides on RiVax are indicated in supplementary Table S1. *, indicates VHHs with toxin-neutralizing activity.
Underline indicates intermediate protection determined by HX-MS.
Subcluster 3.1: Sixteen of the 21 VHHs shared an HX-MS profile involving contact with α-helices
C and G, which we refer to as subcluster 3.1 (Table 3; Table S2; Figures S4 and S5). While the HX-MS
profiles of the VHHs within 3.1 were qualitatively similar, there were quantitative differences that
may be significant in terms of neutralizing activity. For example, V1D3, one of the two VHHs with
toxin-neutralizing activity, had a binding pattern virtually identical to IB2 in that it strongly protected
α-helix C (peptides 54–55, residues 127–135) and the C-terminus region (peptides 132–134, residues
249–255) (Figures 4 and 5). Moreover, V1D3 demonstrated intermediate protection of α-helix G (peptide
91, residues 205–210), as well as strands i and j (peptides 112–116, residues 226–243). In contrast, V6B4,
an antibody without toxin-neutralizing activity, strongly protected RiVax residues 119 to 133 (peptides
48–51), corresponding to α-helix C, and residues 205–217 (peptides 91 to 102), corresponding to α-helix
G (Figures 4 and 5). However, V6B4 differed from V1D3 in three respects. First, V6B4 had stronger
protection of α-helix G than C, as compared to V1D3. Second, V1D3 interacted with β-strands i and
j, while V6B4 did not, possibility indicating that V1D3 overall contact interface with RiVax is larger
than V6B4’s. Finally, the patterns of protection in α-helix C are distinct. In case of V6B4, the entirety of
α-helix C is strongly protected, while in the case of V1D3 it is only the C-terminal end that is strongly
protected (Figures 4 and 5). V1D3 also caused intermediate protection in the N-terminal end of helix
G, while V6B4 protected all of helix G. It is unclear if these differences in α-helix C and α-helix G
protection explain V1D3’s TNA.
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Figure 5. Epitope localization for two subcluster 3.1 V Hs. HX protection categories shown in
Figure 4 were mapped onto the crystal structure of RiVax for (A) V6B4 and (B) V1D3. The most
relevant secondary structure elements, α-helices C and G and β-strands i and j, are labeled. The color
shading corresponds to strong (deep blue), intermediate (light blue) or no significant protection (gray),
as represented in Figure 4.
The competition ELISA with the panel of RTA-specific mAbs revealed additional degrees of
difference among the 16 VHHs in subcluster 3.1 (Figure 2). Not only was there a clear gradation
of competition with IB2 (range 25–90%), but there were marked disparities with other mAbs. For
example, V1B11 is a potent inhibitor of WECB2, V1D3 stood out because of competition with SWB1,
while JNM-D1 competes strongly with SyH7. Because the footprints of all 10 anti-RTA mAbs have
been defined, we can infer from the various inhibition profiles how different VHHs engage RTA. Thus,
looking directly at the RTA active site, with RTB oriented on the bottom, we predict that V1B11 likely
approaches RTA from the top down, V1D3 likely from top left, and JNM-D1 likely from bottom left.
Subcluster 3.2: Three VHHs, V6D8, V6F12 and V7H7, were grouped within subcluster 3.2 based
on a common HX-MS profile encompassing α-helices B, C and G (Figures 6 and 7). For example, V6D8
strongly protected α-helices B (residues 92–107; peptides 35–39), C (residues 123–135; peptides 49–54),
G (residues 211–217; peptides 102) and a short region near the C-terminus of α-helix G (residues
247–255, peptides 129–134). V6F12 shared a binding profile with V6D8, which was not surprising since
the two VHHs are likely from the same B-cell lineage (Table 1; Figure S1). Although the protection
profiles of V6D8, V6F12, and V7H7 were qualitatively similar, and all three VHHs were competed
by IB2 to a similar degree, the magnitudes of protection in the three secondary structural features
were distinct. V6D8 and V6F12 interacted primarily with α-helices B and C, and secondarily with
α-helix G. V7H7, by contrast, primarily protected several overlapping peptides in α-helix G, and
secondarily protected α-helices B and C (except for one peptide in α-helix C). Finally, HX-MS indicated
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that V6D8, V6F12, and V7H7 each contact α-helix B, which has been postulated as being a neutralizing
hotspot on RTA [22]. However, none of the VHHs within this subcluster had any detectable TNA,
possibly because their binding affinities do not achieve a minimum threshold required to inactivate
ricin. Other previously described VHHs that engage α-helix B and have potent toxin-neutralizing
activities each have binding affinities of less than 200 pM, including JIV-F5 (19 pM), JIY-E5 (191 pM),
and JPF-A9 (102 pM) [21,22,33]. This contrasts with V7H7, the strongest binder in subcluster 3.2, which
has a binding affinity of ~500 pM.
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Subcluster 3.3: The third subcluster is populated by V6D4, which had weak toxin-neutralizing
activity (IC50 ~200 nM) in the Vero cell cytotoxicity assay. HX-MS analysis demonstrated strong
protection of α-helix G (peptide 102, residues 211–217) and intermediate protection of α-helix B
(peptides 35–39, residues 92–107). V6D4 also protected a short region in the C-terminus of RiVax,
but not α-helix C itself (Figure 8). Whether V6D4’s neutralizing activity is a result of contact with
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α-helix B is unclear, though its high affinity for ricin (Kd = 222 pM) may put it above any relevant
affinity threshold.
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JNM-A11 did not neutralize ricin, despite a strong binding affinity (Kd = 212 pM). Since JNM-A11 
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Figure 8. Epitope mapping of V6D4 from subcluster 3.3. (A) Relative levels of protection of RiVax
peptides by V6D4 as defined by HX-MS. The color shading corresponds to strong (deep blue),
intermediate (light blue) or no significant protection (gray), as represented in Figure 4. (B) The
HX protection categories, as shown in panel A, were mapped onto the crystal structure of RiVax.
Secondary structures α-helices B and G are labeled.
Subcluster 3.4: The fourth subcluster is also populated by a single antibody, JNM-A11. JNM-A11
showed strong protection of residues in RTA’s α-helix ( e ti es 49–51; residues 124–133) and
intermediate protection of the N-terminal region of - li ( tides 70 and 71; residues 162–168)
and β-strand h (peptides 45 and ; s 108–1 2) (Figure 9). JNM-A11 did not protect α-helix
G, ti tes it fro the 20 other V Hs in cluster 3. JNM-A11’s competition profile against
a panel of RTA-specific i c t lts obtained by HX-MS. Namely, JNM-A11
competed with both Cluster 1 (PB10, WECB2) cl st r 2 (S B1) mAbs (Figure 2A). Finally,
JNM-A11 did not neutralize ricin, despite a strong binding affinity (Kd = 212 pM). Since JNM-A11
appears to target α-helix C almost exclusively, we infer that contact with α-helix C alone is not sufficient
to affect ricin function.
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4. Discussion
As part of our long-standing effort to generate a comprehensive B-cell epitope map of ricin toxin,
we have characterized 21 unique VHHs that share the common property of being within the shadow of
IB2 based on competition ELISAs. IB2 is a toxin-neutralizing mAb that engages with α-helices C and G
on RiVax and defines so-called epitope cluster 3 [11,18]. Cluster 3 is of interest because it encompasses
the residues on RTA involved in ribosome inactivation [10,34,35]. The 21 VHHs originated from
different ph ge-displayed libraries, each generated from alpacas immunized with ricin toxin antigens,
including RiVax (D. Vance, C. Shoemaker, N. Mantis, manuscript in preparation) [23]. As a result,
of epitope mapping studies by HX-MS, the 21 VHHs were further grouped i to four distinct subclusters
(3.1–3.4) based on their interactions with RiVax α-helix C and α-helix G, as well as other local secondary
structures including α-helix B, α-helix E, and β-strand h (Figure 10). The fact that all 21 VHHs engage
RiVax via α-helix C and/or α-helix G explains the observed competition with IB2 by ELISA (Figure 2).
However, we are unable to explain exactly why V1D3 and V6D4 are the only VHHs within cluster
3 that have toxin-neutralizing activity, since other VHHs have similar footprints on ricin and nearly
identical binding affinities as V1D3 and V6D4 but are devoid of neutralizing activity. We can only
speculate that neutralizing activity is due to specific residue contacts or combinations of contact that
are not apparent by HX-MS epitope mapping methodologies (see below).
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Arg180). Viewing the active site pocket head on, α-helices C (121–135) and G (207–217) would be 
located at 10 o’clock and 7 o’clock, respectively (Figure 10). Thus, antibodies in subclusters 3.1, 3.2 
and 3.3 would be expected to physically occlude (straddle) or even occupy the active site pocket, 
whereas the single antibody (JNM-A11) in subcluster 3.4 is probably associated with upper rim (11 
o’clock) of the active site (Figure 10). To examine these possibilities, efforts are ongoing to solve the 
X-ray crystal structures of all 21 of these VHHs in complex with RTA. 
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cell epitope mapping. On the upside, the HX-MS pipeline proved to be robust and relatively high 
throughput due to the fact that we had already established a RiVax peptide map and baseline HX 
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Figure 10. Visual representation subcluster 3 binding sites on ricin toxin. (A) Linear depiction of RTA
with arrows denoting β-strand secondary structure and coils indicating α-helices, as per Protein Data
Bank (PDB) format. Below, the colored bars denote epitope coverage for each of the VHH subclusters
3.1–3.4. The colors correspond to secondary structures highlighted in panel B. Horizontal line below
refers to RTA amino acid residue number. (B) Surface representations of ricin (PDB 2AAI) using PyMol
showing the regions of protection for each of the four subclusters (3.1–3.4). Colors are as follows: RTA,
light gray; RTB, dark gray; active site, yellow; α-helix B, blue; α-helix C, red; α-helix G, green; α-helix
E, orange; β-strand h, purple.
RTA’s active site consists of a large solvent-exposed cleft on one face of the molecule [10,34–37].
Active site residues include Tyr80, Tyr123, Arg180, and Glu177, which are involved in stacking the
purine ring of target adenosine moiety (Tyr80, Tyr123) and transition state stabilization (Glu177,
Arg180). Viewing the active site pocket head on, α-helices C (121–135) and G (207–217) would be
located at 10 o’clock and 7 o’clock, respectively (Figure 10). Thus, antibodies in subclusters 3.1, 3.2 and
3.3 would be expected to physically occlude (straddle) or even occupy the active site pocket, whereas
the single antibody (JNM-A11) in subcluster 3.4 is probably associated with upper rim (11 o’clock) of
the active site (Figure 10). To examine these possibilities, efforts are ongoing to solve the X-ray crystal
structures of all 21 of these VHHs in complex with RTA.
The current study also highlights both the advantages and shortcomings of HX-MS for use
in B-cell epitope mapping. On the upside, the HX-MS pipeline proved to be robust and relatively
high throughput due to the fact that we had already established a RiVax peptide map and baseline
HX kinetics [11]. HX-MS was able to assess RiVax-VHH binding in solution and parse cluster 3
epitopes into four subclusters that we are currently compared to interaction sites observed by X-ray
crystallography. On the other hand, HX-MS provides only peptide level resolution in terms of defining
actual antibody contacts on the target antigen and cannot reveal subtle interactions that may ultimately
be of consequence to toxin-neutralizing activity. As a case in point, we recently described two VHHs
(JPF-A9 and V8A7) with essentially identical HX-MS profiles but that differ in both binding affinity
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and toxin-neutralizing activity as a result of a single residue difference in CDR2 [33]. Coupling
HX-MS with high density competition ELISAs and/or site-directed mutagenesis can significantly
improve epitope definition [23,38–40]. The magnitude of HX protection will depend on the affinity
and kinetics of binding. Lower affinity generally leads to weaker protection against HX, thereby
making it more difficult to resolve the epitope from allosteric effects. However, in practice we have
found that introduction of point mutations in VHHs that led to ~10-fold differences in binding affinity
(e.g., 0.4 to 4 nM) did not notably alter their HX profiles [31]. Since each epitope mapping data set is
treated independently, our analysis still finds the most strongly protected regions.
At this point in time, more than 30 alpaca B-cell epitopes and more than a dozen murine B-cell
epitope on RTA have been reported [18,19,21–23,41–44]. The availability of this dense epitope map
and a collection well characterized antibodies has already proven to have utility in terms of pre-clinical
evaluation of RiVax and other candidate RTA-based vaccine antigens. In one instance the mAbs were
used as tools in competition ELISAs to demonstrate epitope use within humans and non-human
primates vaccinated with RiVax [14]. More recently, the mAbs were used to evaluate the integrity
of key neutralizing epitopes on RiVax during long-term storage [25]. The 21 VHHs described here
focused around RTA’s active site now add to that growing list of critical reagents.
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